Speakers' Presentations
Plenary Sessions – April 28 & 29
April 28th − Plenary 1 − 0900 – 1030 − Beyond the Evidence: Making Tough Decisions
April 28th − Plenary 2 − 1330 – 1500 − Packaging Evidence for Maximum Impact: Lessons from Different Fields
April 29th − Plenary 1 − 0830 – 1000 − Innovation and Health Technology
April 29th − Plenary 2 − 1300 – 1415 − Making Tough Decisions: Where Do We Go From Here?
Concurrent Sessions - April 28 & 29
Session 1: April 28th − 1100 – 1230 − Optimal Drug Therapy: Approcahes and Tools
Session 2: April 28th − 11:00 – 12:30 − Re-Use of Single-Use Medical Devices in Canada: Using Evidence to Inform Policy
- Hussein Noorani
- Julie Polisena − National Survey and Clinical Review
- Philip Jacobs (Hussein Noorani) − Economics
- Sudha Kutty − Implications for Hospitals
- Philip Neufeld − Implications for Health Policy
Session 3: April 28th − 1100 – 1230 − Decision Processes: Inputs and Issues
- Shawn Bugden − One World, One Evidence-Base, Many Decisions: Bevacizumab for the Treatment of Metastatic Colorectal Cancer
- Josephine McMurray, Ian McKillop − Hospital Information and Communication Technology (ICT) Investments: Rational Choice or Rock, Paper, Scissors?
- Fiona Clement − A Tri-Nation Comparison of Pharmacoeconomic Submissions
Session 4: April 28th − 1100 – 1230 − Networks for the Production and Use of HTA
- Henry Borowski − HTS Policy Forum
- Sarah Hayward − SEARCH Canada: Using Networks in the White Space
- Don Husereau − Health Technology Analysis Exchange
- Egon Jonsson − WHO, INAHTA, Alberta Health Evidence Network
Session 5: April 28th − 1100 – 1230 − Economics, Expenditures and Cost-Effectiveness
- Moshen Sadatsafavi − Cost-Effectiveness of Therapy with Combinations of Long-Acting Bronchodilators and Inhaled Steroids for Treatment of COPD: An Economic Evaluation of the OPTIMAL Study
- Greg McComb − NPDUIS Drug Trend Report, 2005/06
- Carolyn Green − Achieving Rigour and Relevance in a Health Technology Assessment (HTA) of Double Balloon Endoscopy
Session 6: April 28th − 1530 – 1700 − Following the Evidence Road: Implementation of Evidence-Based Decisions for Personal Home Care Formularies
Session 7: April 28th − 1530 – 1700 − The Methodological Conundrum of Guideline Adaptation: How to Align Evidence Quality with Recommendations
Session 8: April 28th − 1530 – 1700 − Knowledge Transfer: Different Approaches for Different Audiences
- Kaye Andrews, Debbie Bunka − Application of Evidence-based Knowledge: Collaboration between Academic Detailers and Primary Care Pharmacists
- Katharina Kovacs Burns − “Citizen Science”: A Transformative Way of Engaging Consumers & Decision Makers
- Bill Leslie − Rx for Change Interventions Database
Session 9: April 28th − 1530 – 1700 − Evidence, Value, Context
- Janice Butler − Newfoundland and Labrador’s Contextualized Health Research Synthesis Program: An Innovative Collaborative Approach to HTA Synthesis for Policy Makers
- Mireille Goetghebeur − Evidence and Value: Impact on DEcisionMaking (EVIDEM)—A Practical Framework Applying Multi-criteria Decision Analysis (MCDA) to Support Health Care Decision Making
- Heather Bennett − Implementation of the GRADE Method for Developing Recommendations on the Use of Insulin Analyogues for the Management of Diabetes Mellitus
Session 10: April 28th − 1530 – 1700 − Perspectives on the Common Drug Review
- Angela Rocchi − CEDAC Recommendations: Does Cost-Effectiveness Matter?
- David Rumel − Common Drug Review Case Studies that Challenge CADTH’s Reputation
- Braden Manns − Common Drug Review (CDR) Transparency Initiatives
Session 11: April 29th − 1030 – 1200 − From Evidence to Policy to Implementation to Behavioural Change
Session 12: April 29th − 1030 – 1200 − HTA on the Frontlines
- Paule Poulin − Revision of a Local Health Technology Assessment Program by Departments within the Calgary Region Health
- Chantale Simard − The Organizational Model of the Technology and Health Intervention Methods Evaluation Unit at the Centre Hospitalier Universitaire de Québec: An Innovative Approach to Shared, Evidence-based Decision Making
- Yves Amyot − The Launch of a Demonstration-based Technology Evaluation Unit
Session 13: April 29th − 1030 – 1200 − Innovation and Emerging Technologies
- Janet Joy, Melanie Leung − A Question of Balance: HTA versus Innovation
- Diponkar Banerjee − Bridging Genomics and Therapy—Creating a Theranostics Paradigm
- Rebecca Szilagyi − The New Drug Pipeline Monitor: A New Phase for the National Prescription Drug Utilization Information System (NPDUIS)
Session 14: April 29th − 1030 – 1200 − Priority Setting
- Rebecca Bruni − When Evidence Is Not Enough: Involving the Public in the Priority-Setting of a Wait Time Management Initiative to Enhance Legitimacy and Fairness
- Shannon Sibbald − Evaluating Success in Priority Setting
- Neale Smith − Using Evidence in Resource Allocation Decisions: Empirical Studies from British Columbia’s Health Authorities
Session 15: April 29th − 1030 – 1200 − Methodological Issues
- Elena Lungu − The Use of the World Health Organization’s Defined Daily Dose in Drug Costs and Utilization Analyses
- Jennifer Pereira − Methods for Individualizing the Integrated Benefit and Harm of Warfarin
- Eric Nauenberg − The $50,000/QALY Threshold Reconsidered: A Retrospective on Klarman’s Original Paper with an Eye to the Future